The global post-traumatic stress disorder treatment market is set for significant growth, with its valuation expected to climb from USD 16.8 billion in 2023 to an impressive USD 27.37 billion by 2033, reflecting a robust CAGR of 5% during the forecast period from 2023 to 2033. This surge is attributed to the continuous innovation in therapeutic approaches and the increasing global prevalence of PTSD.
Historically, from 2018 to 2022, the PTSD treatment market registered a moderate growth rate of 3.3% CAGR, setting the stage for the accelerated expansion now anticipated. Advances in pharmacological and non-pharmacological therapies, alongside growing awareness and diagnosis rates, are key drivers of this upward trajectory.
According to the National Center for PTSD, approximately 7-8% of the US population will experience PTSD at some point in their lives, with higher rates among military veterans and individuals who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been identified as a potential driver of PTSD, with healthcare workers, frontline responders, and individuals who have been directly affected by the virus at increased risk.
There is also a growing focus on the use of digital therapeutics and other non-pharmacological interventions for the treatment of PTSD. One example is the use of virtual reality exposure therapy (VRET), which has shown promising results in reducing PTSD symptoms by allowing individuals to confront their trauma in a safe and controlled environment. Several companies, including Limbix and Psious, are developing VRET platforms for the treatment of PTSD and other mental health conditions.
Key Takeaways from the Market Study:
- The post-traumatic stress disorder (PTSD) treatment market is expected to grow at a value of 5% CAGR in the forecast period 2023 to 2033.
- By drug class, antidepressants are expected to hold 41% of the market share in 2023 for post-traumatic stress disorder (PTSD) treatment market.
- North America is expected to possess 43% market share for post-traumatic stress disorder (PTSD) treatment market in 2023.
- Europe post-traumatic stress disorder (PTSD) treatment market size is expected to possess 42% market share in 2023.
“As the prevalence of PTSD continues to rise, the need for effective and accessible treatments will only become more pressing. While there is still much work to be done, the growing focus on PTSD treatment is a positive step forward in improving the lives of individuals affected by this debilitating condition,” states an FMI analyst.
High Demand for Market Insights: Discover Comprehensive Trends in Our Full Report!
Competitive Landscape:
Key players in the post-traumatic stress disorder (PTSD) treatment market are Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc, Viatris Inc., Jubilant Pharmova
- Otsuka has also partnered with the U.S. Department of Veterans Affairs (VA) to conduct a clinical trial of a medication called samidorphan (ALKS 5461) for the treatment of PTSD. Samidorphan is an opioid system modulator that is being investigated for its ability to reduce symptoms of PTSD, including anxiety, depression, and hyperarousal.
- Bionomics Limited is a biopharmaceutical company that has developed a medication called BNC210, which is being investigated as a potential treatment for PTSD (Post-Traumatic Stress Disorder). BNC210 is a small molecule drug that acts as a negative allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR), which is thought to play a role in the development and maintenance of PTSD symptoms.
Key Segments Profiled in the Post-Traumatic Stress Disorder (PTSD) Treatment Industry Survey:
By Drug Class:
- Antidepressants
- Anti-anxiety Drugs
- Antipsychotics
- Other Drug Classes
By Distribution Channel:
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube